

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Alexandria, VA 22313, on


Jane A. Walker

May 3, 2004
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Rothenberg et al.
Application No.: 10/752,659
Filed: January 7, 2004
Title: **CYTOKINE INHIBITION OF EOSINOPHILS**
Art Unit: 1614
Examiner: Unknown
Conf. No.: 4105
Atty. Docket No.: CMC-161

Cincinnati, Ohio

May 3, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
FILED PURSUANT TO 37 CFR §§ 1.56 AND 1.97-1.98

Sir:

In accordance with the duty of candor and good faith imposed by 37 C.F.R. §1.56, and the means of complying with that duty according to 37 C.F.R. §§1.97 and 1.98, Applicants call the references listed on the attached PTO-1449 form to the attention of the United States Patent and Trademark Office in connection with the above-identified patent application. Applicants have enclosed a copy of the cited references and request that the Examiner consider the cited references and make an independent evaluation of their materiality.


A first Office Action has not yet been issued. Therefore, Applicants do not believe that any fees are due in connection with this submission. However, if such fees are necessary, the Commissioner is authorized to charge any necessary fees to Deposit Account 23-3000.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.

By: Beverly A. Lyman
Beverly A. Lyman, Ph.D.
Reg. No. 41,961

Wood, Herron & Evans, L.L.P.
2700 Carew Tower
Cincinnati, OH 45202
513 241-2324
513 421-7269 facsimile
K:\CMC\161\IDS.wpd

SUBSTITUTE FORM PTO-1449 (MODIFIED) 	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161	SERIAL NO. 10/752,659
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Mark Elliot Rothenberg et al.	
	(Use several sheets if necessary)		FILING DATE January 7, 2004	GROUP Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A						
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	A.L						
	A.M						
	A.N						
	A.O						
	A.P						
	A.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

A.R	Combadiere et al., <u>Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor</u> , J. Bio. Chem. 270:16491-16494 (1995) and 271:11034 (1996)
A.S	Daugherty et al., <u>Cloning, Expression, and Characterization of the Human Eosinophil Eotaxin Receptor</u> , J. Exp. Med. 183:2349-2354 (1996)
A.T	Forssmann et al., <u>Eotaxin-2, a Novel CC Chemokine that is Selective for the Chemokine Receptor CCR3, and Acts Like Eotaxin on Human Eosinophil and Basophil Leukocytes</u> , J. Exp. Med. 185:2171-2176 (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161		SERIAL NO. 10/752,659	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Mark Elliot Rothenberg et al.			
(37 CFR 1.98(b))				FILING DATE January 7, 2004		GROUP Unknown	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A						
	B.B						
	B.C						
	B.D						
	B.E						
	B.F						
	B.G						
	B.H						
	B.I						
	B.J						
	B.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L						
	B.M						
	B.N						
	B.O						
	B.P						
	B.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	B.R	Gerber et al., <u>Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils</u> , Curr. Biol. 7:836-843 (1997)					
	B.S	Heath et al., <u>Chemokine Receptor Usage by Human Eosinophils</u> , J. Clin. Invest. 99:178-184 (1997)					
	B.T	Jinquan et al., <u>CXCR3 Expression and Activation of Eosinophils: Role of IFN-g-Inducible Protein-10 and Monokine Induced by IFN-g</u> , J. Immunol. 165:1548-56 (2000)					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161	SERIAL NO. 10/752,659
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Mark Elliot Rothenberg et al.	
(Use several sheets if necessary)					
(37 CFR 1.98(b))				FILING DATE January 7, 2004	GROUP Unknown

U.S. PATENT DOCUMENTS																	
EXAMINER INITIAL	C.A.	C.B.	C.C.	C.D.	C.E.	C.F.	C.G.	C.H.	C.I.	C.J.	C.K.	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS											
C.L.	C.M.	C.N.	C.O.	C.P.	C.Q.	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)		
C.R	Kitaura et al., <u>Molecular Cloning of a Novel Human CC Chemokine (Eotaxin-3) That Is a Functional Ligand of CC Chemokine Receptor 3</u> , J. Biol. Chem. 274:27975-80 (1999)	
C.S	Loetscher et al., <u>The Ligands of CXC Chemokine Receptor 3, I-TAC, Mig, and IP10, Are Natural Antagonists for CCR3</u> , J. Biol. Chem. 276:2986-91 (2001)	
C.T	Lukacs, <u>Role of Chemokines in the Pathogenesis of Asthma</u> , Natue Rev. Immunol. 1:108-16 (2001)	

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161	SERIAL NO. 10/752,659		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Mark Elliot Rothenberg et al.			
(Use several sheets if necessary)							
(37 CFR 1.98(b))				FILING DATE January 7, 2004	GROUP Unknown		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	D.A						
	D.B						
	D.C						
	D.D						
	D.E						
	D.F						
	D.G						
	D.H						
	D.I						
	D.J						
	D.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	D.L						
	D.M						
	D.N						
	D.O						
	D.P						
	D.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	D.R	Luster, <u>Chemokines - Chemotactic Cytokines That Mediate Inflammation</u> , N. Eng. J. Med. 338:436-445 (1998)					
	D.S	Matthews et al., <u>Eotaxin is required for the baseline level of tissue eosinophils</u> , Proc. Natl. Acad. Sci. U.S.A. 95:6273-78 (1998)					
	D.T	Mishra et al., <u>An etiological role for aeroallergens and eosinophils in experimental esophagitis</u> , J. Clin. Invest. 107:83-90 (2001)					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161	SERIAL NO. 10/752,659		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Mark Elliot Rothenberg et al.			
(Use several sheets if necessary)							
(37 CFR 1.98(b))				FILING DATE January 7, 2004	GROUP Unknown		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	E.A						
	E.B						
	E.C						
	E.D						
	E.E						
	E.F						
	E.G						
	E.H						
	E.I						
	E.J						
	E.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	E.L						
	E.M						
	E.N						
	E.O						
	E.P						
	E.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	E.R	Nickel et al., <u>Chemokines and allergic disease</u> , J. Allergy Clin. Immunol. 104:723-742 (1999)					
	E.S	Patel et al., <u>Molecular and Functional Characterization of Two Novel Human C-C Chemokines as Inhibitors of Two Distinct Classes of Myeloid Progenitors</u> , J. Exp. Med. 185:1163-1172 (1997)					
	E.T	Ponath et al., <u>Molecular Cloning and Characterization of a Human Eotaxin Receptor Expressed Selectively on Eosinophils</u> , J. Exp. Med. 183:2437-2448 (1996)					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161		SERIAL NO. 10/752,659	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Mark Elliot Rothenberg et al.			
(37 CFR 1.98(b))				FILING DATE January 7, 2004		GROUP Unknown	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	F.A						
	F.B						
	F.C						
	F.D						
	F.E						
	F.F						
	F.G						
	F.H						
	F.I						
	F.J						
	F.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	F.L						
	F.M						
	F.N						
	F.O						
	F.P						
	F.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)	
F.R	Pope et al., IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism, J. Allergy Clin. Immunol. 108:594-601 (2001)
F.S	Power et al., The chemokine system: novel broad-spectrum therapeutic targets, Curr. Opin. Pharmacol. 1:417-24 (2001)
F.T	Rollins, Chemokines, Blood 90:909-928 (1997)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161		SERIAL NO. 10/752,659	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Mark Elliot Rothenberg et al.			
(Use several sheets if necessary)							
(37 CFR 1.98(b))				FILING DATE January 7, 2004		GROUP Unknown	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	G.A						
	G.B						
	G.C						
	G.D						
	G.E						
	G.F						
	G.G						
	G.H						
	G.I						
	G.J						
	G.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	G.L						
	G.M						
	G.N						
	G.O						
	G.P						
	G.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	G.R	Rothenberg et al., <u>Murine eotaxin: An eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression</u> , Proc. Natl. Acad. Sci. 92:8960-8964 (1995)					
	G.S	Rothenberg et al., <u>Eotaxin Triggers Eosinophil-Selective Chemotaxis and Calcium Flux via a Distinct Receptor and Induces Pulmonary Eosinophilia in the Presence of Interleukin 5 in Mice</u> , Molecular Medicine 2:334-348 (1996)					
	G.T	Rothenberg, <u>Eotaxin: An Essential Mediator of Eosinophil Trafficking into Mucosal Tissues</u> , Am. J. Respir. Cell Mol. Biol. 21:291-295 (1999)					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161	SERIAL NO. 10/752,659		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Mark Elliot Rothenberg et al.			
(Use several sheets if necessary)				FILING DATE January 7, 2004	GROUP Unknown		
(37 CFR 1.98(b))							
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	H.A						
	H.B						
	H.C						
	H.D						
	H.E						
	H.F						
	H.G						
	H.H						
	H.I						
	H.J						
	H.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	H.L						
	H.M						
	H.N						
	H.O						
	H.P						
	H.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	H.R	Rothenberg, <u>Eosinophilia</u> , N. Eng. J. Med. 338:1592-1600 (1998)					
	H.S	Rothenberg, <u>Targeted Disruption of the Chemokine Eotaxin Partially Reduces Antigen-induced Tissue Eosinophilia</u> , J. Exp. Med. 185:785-790 (1997)					
	H.T	Sallusto et al., <u>Selective Expression of the Eotaxin Receptor CCR3 by Human T Helper 2 Cells</u> , Science 277:2005-2007 (1997)					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161		SERIAL NO. 10/752,659	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Mark Elliot Rothenberg et al.			
(Use several sheets if necessary)							
(37 CFR 1.98(b))				FILING DATE January 7, 2004		GROUP Unknown	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	I.A						
	I.B						
	I.C						
	I.D						
	I.E						
	I.F						
	I.G						
	I.H						
	I.I						
	I.J						
	I.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	I.L						
	I.M						
	I.N						
	I.O						
	I.P						
	I.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	I.R	Shinkai et al., <u>A Novel Human CC Chemokine, Eotaxin-3, Which Is Expressed in IL-4-Stimulated Vascular Endothelial Cells, Exhibits Potent Activity Toward Eosinophils</u> , J. Immunol. 163:1602-1610 (1999)					
	I.S	Stellato et al., <u>Characterization of CCR3 Expression on Human Airway Epithelial Cells</u> , J. Allergy Clin. Immunol. 103 (No. 1 Pt. 2): S194 (1999)					
	I.T	Uguccioni et al., <u>High Expression of the Chemokine Receptor CCR3 in Human Blood Basophils Role in Activation by Eotaxin, MCP-4, and Other Chemokines</u> , J. Clin. Invest. 100:1137-1143 (1997)					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161	SERIAL NO. 10/752,659		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Mark Elliot Rothenberg et al.			
(Use several sheets if necessary)							
(37 CFR 1.98(b))				FILING DATE January 7, 2004	GROUP Unknown		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	J.A						
	J.B						
	J.C						
	J.D						
	J.E						
	J.F						
	J.G						
	J.H						
	J.I						
	J.J						
	J.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	J.L						
	J.M						
	J.N						
	J.O						
	J.P						
	J.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	J.R	Youn et al., <u>Molecular Cloning of Leukotactin-1: A Novel Human beta-Chemokine, a Chemoattractant for Neutrophils, Monocytes, and Lymphocytes, and a Potent Agonist at CC Chemokine Receptors 1 and 3</u> , J. Immunol. 159:5201-5205 (1997)					
	J.S	Zhang et al., <u>Differential Effects of Leukotactin-1 and Macrophage Inflammatory Protein-1alpha on Neutrophils Mediated by CCR1</u> , J. Immunol. 162:4938-4942 (1999)					
	J.T	Zhu et al., <u>Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production</u> , J. Clin. Invest. 103:779-788 (1999)					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161		SERIAL NO. 10/752,659	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Mark Elliot Rothenberg et al.			
(Use several sheets if necessary)							
(37 CFR 1.98(b))				FILING DATE January 7, 2004		GROUP Unknown	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	K.A						
	K.B						
	K.C						
	K.D						
	K.E						
	K.F						
	K.G						
	K.H						
	K.I						
	K.J						
	K.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	K.L						
	K.M						
	K.N						
	K.O						
	K.P						
	K.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	K.R	Zimmermann et al., <u>CC Chemokine Receptor-3 Undergoes Prolonged Ligand-induced Internalization</u> , J. Biol. Chem. 274:12611-12618 (1999)					
	K.S	Zimmermann et al., <u>Murine Eotaxin-2: A Constitutive Eosinophil Chemokine Induced by Allergen Challenge and IL-4 Overexpression</u> , J. Immunol. 165:5839-5846 (2000)					
	K.T	Zimmermann et al., <u>Molecular Analysis of CCR-3 Events in Eosinophilic Cells</u> , J. Immunol. 164:1055-1064 (2000)					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							